1-chloro-5-fluorohexane | 97226-93-2

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 1-chloro-5-fluorohexane
• CAS: 97226-93-2
• 化学式: C₆H₁₂ClF
• 分子量: 138.613
• InChiKey: REMHIUVGOFZABX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-己烯 、 N,N-二氯-N-甲胺 、 三氟化硼 以7%的产率得到
  参考文献：
  名称：

  HEASLEY, G. E.;JANES, J. M.;STARK, S. R.;ROBINSON, B. L.;HEASLEY, V. L.;S+, TETRAHEDRON LETT., 1985, 26, N 15, 1811-1814

  摘要：

  DOI：

文献信息

• Elemental fluorine. Part 19: Electrophilic fluorination of hexyl derivatives bearing electron withdrawing groups
  作者：Richard D. Chambers、Mandy Parsons、Graham Sandford、Emmanuelle Thomas、Jelena Trmcic、John S. Moilliet

  DOI：10.1016/j.tet.2006.03.113

  日期：2006.7

  Reaction of a series of model hexyl derivatives of the form C6H13–X (X=Cl, Br, I, CO2Me, COMe, CHO) with both elemental fluorine and Selectfluor™ was studied in order to assess the impact of electron withdrawing functional groups upon fluorination of an alkyl chain. Fluorination generally occurs at secondary sites, with a slight preference for those that are furthest removed from the electron withdrawing

  研究了一系列形式为C 6 H 13 –X（X = Cl，Br，I，CO 2 Me，COMe，CHO）的模型己基衍生物与元素氟和Selectfluor™的反应，以评估氟的影响。烷基链氟化时的吸电子官能团。氟化通常发生在次要位置，与亲电子取代过程一致，略微偏爱从吸电子基团离得最远的位置，尽管在大多数情况下会获得氟化产物的混合物。
• Boron trifluoride promoted reactions of n-haloelectrophiles with alkenes
  作者：Gene E. Heasley、J. Mark Janes、Stephen R. Stark、Brian L. Robinson、Victor L. Heasley、Dale F. Shellhamer

  DOI：10.1016/s0040-4039(00)94744-0

  日期：1985.1

  N-Haloelectrophiles react with alkenes in the presence of boron rifluoride etherate to give halofluorides and N-halo adducts.

  N-卤代亲电子试剂在氟氟化硼醚化物的存在下与烯烃反应，生成卤代氟化物和N-卤代加合物。
• Substituted xanthine derivatives
  申请人：Tung Roger D.

  公开号：US20090239886A1

  公开（公告）日：2009-09-24

  This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

  本发明涉及新型化合物，即取代黄嘌呤衍生物及其药学上可接受的盐。例如，本发明涉及新型取代黄嘌呤衍生物，它们是戊酰异丙基黄嘌呤的衍生物。本发明还提供了包含本发明中的一种或多种化合物和载体的组合物，以及把所述化合物和组合物用于治疗戊酰异丙基黄嘌呤和相关化合物有益的疾病和病况的方法。
• [EN] SUBSTITUTED XANTHINE DERIVATIVES<br/>[FR] DÉRIVÉS DE XANTHINE SUBSTITUÉS
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2011028835A1

  公开（公告）日：2011-03-10

  This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

  本发明涉及新型化合物，它们是取代黄嘌呤衍生物及其药学上可接受的盐。例如，本发明涉及新型取代黄嘌呤衍生物，它们是戊申酰丙胺的衍生物。本发明还提供了包含本发明化合物之一或多个和载体的组合物以及使用所披露的化合物和组合物治疗戊申酰丙胺和相关化合物有益的疾病和病状的方法。
• SUBSTITUTED XANTHINE DERIVATIVES
  申请人：Tung Roger D.

  公开号：US20110053961A1

  公开（公告）日：2011-03-03

  This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

  本发明涉及一种新型化合物，它们是取代黄嘌呤衍生物及其药学上可接受的盐。例如，本发明涉及一种新型的取代黄嘌呤衍生物，它们是戊酰苄氨基甲基黄嘌呤的衍生物。本发明还提供了包括本发明中的一个或多个化合物和载体的组合物，并且揭示了这些化合物和组合物在治疗戊酰苄氨基甲基黄嘌呤和相关化合物有益的疾病和病症的方法中的应用。